| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Glucosyringic acid targets immune cells, exhibiting immunosuppressive activity. It inhibits the proliferation of mouse B lymphocytes in vitro. However, the specific molecular target is not fully characterized.
|
|---|---|
| ln Vitro |
In vitro, Glucosyringic acid has immunosuppressive activity and inhibits the proliferation of mouse B lymphocytes. However, specific IC50 values and detailed in vitro activity data are not extensively reported.
|
| ln Vivo |
In vivo, Glucosyringic acid is expected to show immunosuppressive effects. However, specific in vivo efficacy data and detailed animal study results are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro assays for Glucosyringic acid involve studying its effects on B lymphocyte proliferation. Cells are treated with various concentrations of the compound, and proliferation is assessed using standard assays such as 3H-thymidine incorporation or MTT.
|
| Cell Assay |
In vitro cellular assays for Glucosyringic acid are performed using mouse B lymphocytes to assess its immunosuppressive activity. Cells are treated with the compound, and proliferation is measured.
|
| Animal Protocol |
In vivo animal studies with Glucosyringic acid would typically be conducted in mouse models of immune disorders to evaluate its immunosuppressive effects. However, specific protocols are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Glucosyringic acid are not extensively reported. It has a molecular weight of 360.31. Specific parameters such as oral bioavailability, half-life, and tissue distribution are not detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Glucosyringic acid is not extensively reported. As a research compound, it is for research use only and not for human therapeutic use. No specific toxicity data are detailed.
|
| References | |
| Additional Infomation |
According to reports, Glucosyringic acid has been found in Oriental clover, maple, and other organisms with available data.
Glucosyringic acid (CAS 33228-65-8) is a compound isolated from Saxifraga Montana H. It has a molecular formula of C15H20O10 and a molecular weight of 360.31. The compound exhibits immunosuppressive activity and inhibits mouse B lymphocyte proliferation in vitro. It is available for research purposes only. |
| Molecular Formula |
C15H20O10
|
|---|---|
| Molecular Weight |
360.3133
|
| Exact Mass |
360.105
|
| CAS # |
33228-65-8
|
| PubChem CID |
10383888
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
611.1±55.0 °C at 760 mmHg
|
| Flash Point |
224.7±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
-1.19
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
OC[C@H]1O[C@@H](OC2C(OC)=CC(C(=O)O)=CC=2OC)[C@H](O)[C@@H](O)[C@@H]1O
|
| InChi Key |
BLKMDORKRDACEI-OVKLUEDNSA-N
|
| InChi Code |
InChI=1S/C15H20O10/c1-22-7-3-6(14(20)21)4-8(23-2)13(7)25-15-12(19)11(18)10(17)9(5-16)24-15/h3-4,9-12,15-19H,5H2,1-2H3,(H,20,21)/t9-,10-,11+,12-,15+/m1/s1
|
| Chemical Name |
3,5-dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7754 mL | 13.8769 mL | 27.7539 mL | |
| 5 mM | 0.5551 mL | 2.7754 mL | 5.5508 mL | |
| 10 mM | 0.2775 mL | 1.3877 mL | 2.7754 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
